# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology com...
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expan...
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighti...
Telomir Pharmaceuticals' stock rises as Telomir-1 shows strong lab results against aggressive triple-negative breast cancer...
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology com...